Lenalidomid Ethypharm

Lenalidomide, the active ingredient in Lenalidomid Ethypharm, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It is used to treat certain blood cancers such as multiple myeloma, mantle cell lymphoma, and myelodysplastic syndromes in adult patients and is approved for use in the European Union.

GNH USA supplies Lenalidomid Ethypharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide acts on malignant plasma cells and related pathways in hematologic malignancies. - Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. - Mantle Cell Lymphoma: used in combination regimens to achieve disease control in adult patients. - Myelodysplastic Syndromes: indicated for patients with deletion 5q cytogenetic abnormality to reduce transfusion dependence.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels that may cause bleeding. - Anemia: decreased red blood cell count leading to fatigue. - Fatigue: general feeling of tiredness. - Diarrhea: loose stools or increased bowel movements. - Rash: mild skin irritation or redness.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers. - Hepatic failure: significant liver enzyme elevation or dysfunction. - Interstitial lung disease: inflammation of lung tissue causing breathing difficulties.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for adverse events. - Monitor blood counts: perform regular CBC to detect neutropenia, thrombocytopenia, or anemia. - Assess thrombotic risk: consider prophylactic anticoagulation in high‑risk patients. - Avoid use in pregnancy: teratogenic potential requires effective contraception. - Evaluate renal and hepatic function: dose adjustments may be needed for impairment. - Store at room temperature: keep in the original pack, protect from moisture.

Lenalidomide may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin): additive bleeding tendency. - CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide plasma levels. - Immunosuppressants (e.g., cyclosporine): potential for enhanced toxicity.